Cargando…
722. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function
BACKGROUND: Patients with chronic liver disease (CLD) have impaired immune function, are prone to community-acquired bacterial pneumonia (CABP), and experience greater morbidity/mortality and healthcare costs than CABP patients without CLD. LEF, a novel pleuromutilin antibiotic (IV/oral) with primar...
Autores principales: | Wicha, Wolfgang, Marbury, Thomas C, Dowell, James A, Lykens, Lori, Leister, Cathie, Ermer, James, Gelone, Steven P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810932/ http://dx.doi.org/10.1093/ofid/ofz360.790 |
Ejemplares similares
-
705. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis
por: Wicha, Wolfgang, et al.
Publicado: (2019) -
Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
por: Wicha, Wolfgang W, et al.
Publicado: (2019) -
699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019) -
Tissue Distribution of [(14)C]-Lefamulin into the Urogenital Tract in Rats
por: Wicha, Wolfgang W., et al.
Publicado: (2022) -
684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)